The EGFR gene is mutated in a considerable proportion of primary lung adenocarcinomas, especially in patients who respond to gefitinib and erlotinib, which are small-molecule EGFR tyrosine kinase inhibitors (TKIs).[3] Patients with sensitive EGFR mutations were recommended for first-line TKI treatment. Here, EGFR is linked to lung adenocarcinoma.